EQT Life Sciences

EQT Life Sciences is an Amsterdam-based life sciences venture capital firm focused on Series A, Series B, and growth-stage investments in biopharmaceutical and medical technology companies developing innovative therapeutics and medical devices, operating as the dedicated life sciences investment platform within the EQT Group. The firm traces its origins to Life Sciences Partners (LSP), the Dutch life sciences venture capital firm founded in 1999, which was acquired by EQT in 2020 and rebranded as EQT Life Sciences. The acquisition gave the team access to EQT's global network, resources, and brand. EQT Life Sciences invests with initial checks from $5 million to $25 million and focuses primarily on novel therapeutic approaches in oncology, immunology, neuroscience, and rare diseases. Portfolio companies include Cerevel Therapeutics, the neuroscience-focused biopharmaceutical company acquired by AbbVie for approximately $8.7 billion in 2024; Halo Diagnostics, a diagnostics technology company; Minerva Neurosciences, a clinical-stage biopharmaceutical company focused on treatments for neurological and psychiatric disorders; and Omeros Corporation. Beyond its original investments, the portfolio includes additional clinical-stage European and global biopharmaceutical companies.